Understanding how kinase-targeted therapies work

Cell Cycle

Volumn 7, Issue 11, 2008, Pages 1560-1563

  Arena, Sabrina ^a   Bardelli, Alberto ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Cancer; Inhibitor; Kinase; MET; Off target effect; Target validation

Indexed keywords

ABELSON KINASE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PANITUMUMAB; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; BINDING SITE; CANCER CELL; CANCER INHIBITION; CATALYSIS; CELL DIFFERENTIATION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; PROTEIN DOMAIN; REVIEW; VALIDATION STUDY;

EID: 45849151687     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.11.6031     Document Type: Review

References (32)

1. Hunter T. Signaling - 2000 and beyond. Cell 2000; 100:113-27.
2. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65.
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-25.
4. Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes Dev 2000; 14:1027-47.
5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912-34.
6. Shaw CJ, Lupski JR. Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. Human molecular genetics 2004; 13:57-64.
7. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nature reviews 2001; 2:127-37.
8. Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochimica et biophysica acta 1998; 1377:25-37.
9. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. British journal of cancer 2006; 94:455-9.
10. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochimica et biophysica acta 1997; 1333:217-48.
11. Parsons JT, Parsons SJ. Protein-tyrosine kinases, oncogenes and cancer. Important advances in oncology 1993; 3-17.
12. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1:727-30.
13. Pratt DJ, Endicott JA, Noble ME. The role of structure in kinase-targeted inhibitor design. Current opinion in drug discovery & development 2004; 7:428-36.
14. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003; 17:2998-3010.
15. Scapin G. Protein kinase inhibition: different approaches to selective inhibitor design. Current drug targets 2006; 7:1443-54.
16. Svoboda P. Off-targeting and other non-specific effects of RNAi experiments in mammalian cells. Current opinion in molecular therapeutics 2007; 9:248-57.
17. Carteni G, Fiorentino R, Vecchione L, Chiurazzi B, Battista C. Panitumumab a novel drug in cancer treatment. Ann Oncol 2007; 18:16-21.
18. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anti-cancer drugs 2008; 19:99-113.
19. Barni S, Petrelli F, Cabiddu M, Cazzaniga ME, Cremonesi M. From the trastuzumab era to new target therapies: beyond revolution. Ann Oncol 2007; 18:1-4.
20. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. The New England journal of medicine 2007; 357:39-51.
21. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nature clinical practice 2004; 1:39-43.
22. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006; 12:7242-51.
23. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann Oncol 2007; 18:35-41.
24. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer letters 2005; 225:1-26.
25. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nature biotechnology 2008; 26:127-32.
26. Arena S, Pisacane A, Mazzone M, Comoglio PM, Bardelli A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2007; 104:11412-7.
27. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006; 66:352-61.
28. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, Severin C, Rangell L, Schwall R, Amler L, Wickramasinghe D, Yauch R. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66:283-9.
29. Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res 2006; 66:3452-5.
30. Olivero M, Valente G, Bardelli A, Longati P, Ferrero N, Cracco C, Terrone C, Rocca-Rossetti S, Comoglio PM, Di Renzo MF. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 1999; 82:640-3.
31. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature reviews 2002; 2:289-300.
32. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004; 23:5387-93.